Spaeth/Richman Contrast Sensitivity Test (SPARCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01300949|
Recruitment Status : Completed
First Posted : February 23, 2011
Last Update Posted : January 30, 2015
|Condition or disease|
Objective: To test a new method of determining contrast sensitivity that does not require visual acuity and tests various areas of the visual field.
Hypothesis: A method of determining contrast sensitivity that does not require letter recognition (as in the Pelli-Robson test) eliminates the confounders of literacy and pattern recognition, and will permit a more valid determination of contrast sensitivity.
Patients will perform SPARCS and Pelli-Robson twice; once each with two separate observers for reproducibility and intra-observer reliability. The order of testing will be randomized to SPARCS, Pelli, Pelli, SPARCS or Pelli, SPARCS, SPARCS, Pelli.
|Study Type :||Observational|
|Actual Enrollment :||315 participants|
|Official Title:||Validation and Reproducibility of Spaeth/Richman Contrast Sensitivity Test|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||April 2014|
- Contrast Sensitivity [ Time Frame: 1 day ]If this instrument is a user-friendly, highly specific and sensitive method of determining contrast sensitivity, without influence of acuity, a major advance will be made. It is conceivable that the test could be used for detection of visual disease globally because of ease of operation and availability. Increasing numbers of studies are showing that contrast sensitivity is highly related to patients' ability to perform activities of daily living. It is anticipated that using this technique may become the standard way of assessing visual ability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300949
|United States, Pennsylvania|
|Wills Eye Institute|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||George L Spaeth, MD||Glaucoma Service, Wills Eye Institute|